{"id":"W4410506512","doi":"10.1097/hep.0000000000001385","title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial","year":2025,"lang":"en","type":"article","venue":"Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; University of Calgary","funders":"","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Medicine; Adverse effect; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immune system; Immunotherapy; Gastroenterology; Nivolumab; Immunology; Cancer; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002046342,0.0007664933,0.001499825,0.0002436881,0.0003790402,0.001029635,0.0008472758,0.0006616221,0.002013263],"category_scores_gemma":[0.001248003,0.0004228607,0.001380809,0.0004178818,0.0007038618,0.0005235912,0.000442547,0.001662571,0.0002297451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121565,"about_ca_system_score_gemma":0.001687236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001799462,"about_ca_topic_score_gemma":0.004408845,"domain_scores_codex":[0.9992606,0.000459265,0.00003219326,0.00009339106,0.00006695857,0.00008758198],"domain_scores_gemma":[0.9987085,0.000267335,0.00033657,0.0001338237,0.00007545788,0.0004783593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9388512,0.0088779,0.02227466,0.0008214561,0.005151704,0.0001405606,0.0001837743,0.001162681,0.004049411,0.0001611589,0.001371624,0.01695398],"study_design_scores_gemma":[0.8386923,0.0708072,0.08052237,0.00007582967,0.003912924,0.0002549038,0.0001415196,0.00247786,0.0014139,0.0002336872,0.001416834,0.00005062074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961082,0.001423907,0.000177031,0.0002150287,0.00005716873,0.0006735012,0.0007050612,0.00002243819,0.0006177254],"genre_scores_gemma":[0.9956018,0.0008183377,0.0006238984,0.0002683334,0.0001022767,0.0008882752,0.0009759409,0.000004797363,0.000716212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002046342,"threshold_uncertainty_score":0.01082224,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02808413389112019,"score_gpt":0.3553463013616205,"score_spread":0.3272621674705004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}